---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000297"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-08-26T23:59:59+00:00"
generated_at: "2026-06-29T07:34:49.514604+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology

## Summary
- USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for "Antigen Specific MRNA Cellular Cancer Vaccines".
- The invention covers modified mRNA encoding immunogenic epitopes, e.g., survivin-derived peptides, to induce intracellular antigen production.
- Patent aims to expand epitope repertoire presented to adaptive immune system, improving likelihood of successful immunity induction.

## SEC filing metadata
- accession: 0001607062-21-000297
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/0001607062-21-000297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/rgbp082621form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000297
- JSON: https://secwatch.observer/filing/0001607062-21-000297.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.